Filing Details

Accession Number:
0001181431-12-043179
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-08-02 14:17:59
Reporting Period:
2012-07-31
Filing Date:
2012-08-02
Accepted Time:
2012-08-02 14:17:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1386858 Hyperion Therapeutics Inc HPTX Pharmaceutical Preparations (2834) 611512713
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1302106 D Ryan Drant 1954 Greenspring Drive
Suite 600
Timonium MD 21093
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-07-31 611,185 $0.00 615,119 No 4 C Indirect See Note 1
Common Stock Acquisiton 2012-07-31 898,808 $0.00 1,513,927 No 4 C Indirect See Note 1
Common Stock Acquisiton 2012-07-31 125,291 $0.00 1,639,218 No 4 X Indirect See Note 1
Common Stock Disposition 2012-07-31 51,119 $0.00 1,588,099 No 4 J Indirect See Note 1
Common Stock Acquisiton 2012-07-31 2,043 $0.00 1,590,142 No 4 C Indirect See Note 1
Common Stock Acquisiton 2012-07-31 2,043 $0.00 1,592,185 No 4 C Indirect See Note 1
Common Stock Acquisiton 2012-07-31 434,096 $0.00 2,026,281 No 4 C Indirect See Note 1
Common Stock Acquisiton 2012-07-31 180,459 $0.00 2,206,740 No 4 C Indirect See Note 1
Common Stock Acquisiton 2012-07-31 177,481 $0.00 2,384,221 No 4 C Indirect See Note 1
Common Stock Acquisiton 2012-07-31 500,000 $10.00 2,884,221 No 4 P Indirect See Note 1
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Note 1
No 4 C Indirect See Note 1
No 4 X Indirect See Note 1
No 4 J Indirect See Note 1
No 4 C Indirect See Note 1
No 4 C Indirect See Note 1
No 4 C Indirect See Note 1
No 4 C Indirect See Note 1
No 4 C Indirect See Note 1
No 4 P Indirect See Note 1
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series C-1 Preferred Stock Disposition 2012-07-31 611,185 $0.00 611,185 $0.00
Common Stock Series C-2 Preferred Stock Disposition 2012-07-31 898,808 $0.00 898,808 $0.00
Common Stock Common Stock Warrant (right to buy) Disposition 2012-07-31 125,291 $0.00 125,291 $4.08
Series C-2 Preferred Stock Preferred Stock Warrant (right to buy) Disposition 2012-07-31 53,787 $0.00 53,787 $9.62
Common Stock Series C-2 Preferred Stock Acquisiton 2012-07-31 53,787 $0.00 53,787 $0.00
Common Stock Series C-2 Preferred Stock Disposition 2012-07-31 51,744 $10.00 51,744 $0.00
Common Stock Series C-2 Preferred Stock Disposition 2012-07-31 2,043 $0.00 2,043 $0.00
Series C-2 Preferred Stock Preferred Stock Warrant (right to buy) Disposition 2012-07-31 53,787 $0.00 53,787 $9.62
Common Stock Series C-2 Preferred Stock Acquisiton 2012-07-31 53,787 $0.00 53,787 $0.00
Common Stock Series C-2 Preferred Stock Disposition 2012-07-31 51,744 $10.00 51,744 $0.00
Common Stock Series C-2 Preferred Stock Disposition 2012-07-31 2,043 $0.00 2,043 $0.00
Common Stock Convertible Promissory Note Disposition 2012-07-31 0 $0.00 434,096 $10.00
Common Stock Convertible Promissory Note Disposition 2012-07-31 0 $0.00 180,459 $10.00
Common Stock Convertible Promissory Note Disposition 2012-07-31 0 $0.00 177,481 $10.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 X Indirect
0 No 4 X Indirect
53,787 No 4 X Indirect
2,043 No 4 J Indirect
0 No 4 C Indirect
0 No 4 X Indirect
53,787 No 4 X Indirect
2,043 No 4 J Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The Reporting Person is a manager of NEA 12 GP, LLC, the sole general partner of NEA Partners 12, Limited Partnership, the sole general partner of New Enterprise Associates 12, Limited Partnership ("NEA 12"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities of the Issuer held by NEA 12 in which the Reporting Person has no pecuniary interest.
  2. Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of convertible preferred stock automatically converted into one share of common stock. The convertible preferred stock had no expiration date.
  3. Immediately prior to the closing, the warrants automatically net exercised by their terms, which allowed the holder to pay the exercise price of the warrants by forfeiting a portion of the exercised warrant shares with a value equal to the aggregate exercise price.
  4. These shares reflect the net exercise of the common stock warrant pursuant to its terms into 74,172 shares of the Issuer's common stock.
  5. Notes and accrued interest in the aggregate of $4,340,965 converted automatically immediately prior to the closing of the Issuer's initial public offering into shares of common stock at a conversion price of $10.00 per share, which is the initial public offering price per share.
  6. Notes and accrued interest in the aggregate of $1,804,594 converted automatically immediately prior to the closing of the Issuer's initial public offering into shares of common stock at a conversion price of $10.00 per share, which is the initial public offering price per share.
  7. Notes and accrued interest in the aggregate of $1,774,817 converted automatically immediately prior to the closing of the Issuer's initial public offering into shares of common stock at a conversion price of $10.00 per share, which is the initial public offering price per share.
  8. Immediately prior to the closing, the warrants automatically net exercised by their terms into Series C-2 preferred stock, which allowed the holder to pay the exercise price of the warrants by forfeiting a portion of the exercised warrant shares with a value equal to the aggregate exercise price. The convertible preferred stock had no expiration date.
  9. These shares reflect the net exercise of the preferred stock warrant pursuant to its terms into 2,043 shares of the Issuer's Series C-2 preferred stock.